AstraZeneca-Oxford COVID-19 Vaccine Under Scanner After Error, Serum Institute Says Indian Trials Going Smooth

AstraZeneca-Oxford COVID-19 Vaccine Under Scanner After Error, Serum Institute Says Indian Trials Going Smooth

India.com

New Delhi: Days after claiming promising results from its Covid-19 vaccine trial earlier this week, drugmaker AstraZeneca is now facing tough questions from experts, especially after the company admitted a manufacturing error by a contractor.

As per updates, the error came to light after AstraZeneca, which is developing the potential Covid-19 vaccine in partnership with Oxford University, revealed different efficacy results from two different dose regimes.

In the two different dose regimens vaccine efficacy was 90 per cent in one and 62 per cent in the other. The higher efficacy regime used a halved first dose and standard second dose.

Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

116180118

Cases

91789222

Recovered

2580494

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019